Cargando…

DOACs vs Vitamin K Antagonists: a Comparison of Phase III Clinical Trials and a Prescriber Support Tool

AIM: The purpose of this article was to systematically review the literature assessing the efficacy and safety of phase III clinical trials for each direct oral anticoagulant versus vitamin K antagonists and to design a “go-to” table for the prescriber. MATERIAL AND METHODS: A systematic review of s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pirlog, Alina-Maria, Pirlog, Cristian Daniel, Maghiar, Marius Adrian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Republic of Macedonia 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6490485/ https://www.ncbi.nlm.nih.gov/pubmed/31049112 http://dx.doi.org/10.3889/oamjms.2019.289

Ejemplares similares

A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC
por: Blin, Patrick, et al.
Publicado: (2015)

Direct oral anticoagulants (DOAC) versus vitamin K antagonist in left ventricular thrombus: An updated meta‐analysis
por: Shrestha, Dhan B., et al.
Publicado: (2023)

New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs)
por: van Gorp, Rick H., et al.
Publicado: (2015)

Appropriateness of DOAC Prescribing Before and During Hospital Admission and Analysis of Determinants for Inappropriate Prescribing
por: Moudallel, Souad, et al.
Publicado: (2018)

Elderly people are inherently sensitive to the pharmacological activity of rivaroxaban: implications for DOAC prescribing
por: Kampouraki, Emmanouela, et al.
Publicado: (2020)

Vitamin-K-antagonist phenprocoumon versus low-dose direct oral anticoagulants (DOACs) in patients with atrial fibrillation: a real-world analysis of German claims data
por: Warkentin, Lisette, et al.
Publicado: (2022)

Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis
por: Noviyani, Rini, et al.
Publicado: (2022)

Hepatitis C Virus Infection and the New Therapeutical Approach
por: DANILESCU, CLAUDIA MONICA, et al.
Publicado: (2021)

Which Renal Function Equation Should Be Used for Prescribing DOACs in Patients With Atrial Fibrillation?
por: Wang, Yilong, et al.
Publicado: (2022)

Editorial: Non-coding genome and endocrinology: from bench to bedside
por: Pirlog, Radu, et al.
Publicado: (2023)

Recent Advances on the Roles of PCSK-9 Inhibitors in the Management of Acute Ischemic Stroke Patients
por: Ilut, Silvina, et al.
Publicado: (2022)

The Glioblastoma CircularRNAome
por: Tirpe, Alexandru, et al.
Publicado: (2023)

Evaluation of the DOAC-Stop® Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests
por: Favresse, Julien, et al.
Publicado: (2018)

Uninterrupted DOACs Approach for Catheter Ablation of Atrial Fibrillation: Do DOACs Levels Matter?
por: Hardy, Michael, et al.
Publicado: (2022)

KRAS mutations as essential promoters of lymphangiogenesis via extracellular vesicles in pancreatic cancer
por: Pirlog, Radu, et al.
Publicado: (2022)

Non-vitamin K antagonist oral anticoagulants vs. vitamin-K antagonists in patients with atrial fibrillation and chronic kidney disease: a nationwide cohort study
por: Laugesen, Emma Kirstine, et al.
Publicado: (2019)

DOAC in COVID-19: Yes or No?
por: Schutgens, Roger E.
Publicado: (2020)

Adverse Events of DOACs in Children
por: Bosch, Alessandra, et al.
Publicado: (2022)

DOAC Dipstick Testing Can Reliably Exclude the Presence of Clinically Relevant DOAC Concentrations in Circulation
por: Margetić, Sandra, et al.
Publicado: (2022)

The myths behind DOAC measurement: Analyses of prescribing information from different regulatory bodies and a call for harmonization
por: Gosselin, Robert C., et al.
Publicado: (2022)

An Updated Meta-Analysis of DOACs vs. VKAs in Atrial Fibrillation Patients With Bioprosthetic Heart Valve
por: Cao, Yalin, et al.
Publicado: (2022)

Development of a Software for Treat-To-Target Strategy Implementation and Increasing Quality of Life in Patients with Inflammatory Bowel Disease
por: POPA, DENISA ELENA, et al.
Publicado: (2020)

The Influence of the Inflammatory Bowel Diseases on the Perceived Stress and Quality of Life in a Sample of the South-Western Romanian Population
por: POPA, DENISA-ELENA, et al.
Publicado: (2022)

DOACs – advances and limitations in real world
por: Lee, Lai Heng
Publicado: (2016)

DOAC drug interactions management resource
por: Chadha, Ayush, et al.
Publicado: (2022)

The Effect of Switching to Long-Acting Injection (LAI) Antipsychotic Therapy on Patients with Schizophrenia
por: STRUNOIU, LIVIA MIHAELA, et al.
Publicado: (2021)

Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
por: Hohnloser, Stefan H, et al.
Publicado: (2019)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

Neurobiological and pharmacological arguments for customization of cognitive behavioral psychotherapy in the treatment of major depressive disorder
por: Ristea, Silvia, et al.
Publicado: (2021)

The Roles of the Colon Cancer Associated Transcript 2 (CCAT2) Long Non-Coding RNA in Cancer: A Comprehensive Characterization of the Tumorigenic and Molecular Functions
por: Pirlog, Radu, et al.
Publicado: (2021)

Minimally Interrupted Non-Vitamin K Antagonist Oral Anticoagulants vs. Bridging Therapy and Uninterrupted Vitamin K Antagonists During Atrial Fibrillation Ablation: A Retrospective Single-Center Study
por: Tang, Lihong, et al.
Publicado: (2020)

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation
por: Cappato, Riccardo, et al.
Publicado: (2015)

Corrigendum to: Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
Publicado: (2019)

New Oral Anticoagulants vs. Vitamin K Antagonists Among Patients With Cardiac Amyloidosis: Prognostic Impact
por: Cariou, Eve, et al.
Publicado: (2021)

Bariatric Surgery can Lower the Efficacy of DOACs
por: Bitar, Zouheir Ibrahim, et al.
Publicado: (2020)

Laboratory Monitoring of Direct Oral Anticoagulants (DOACs)
por: Dunois, Claire
Publicado: (2021)

Depressive and Anxious Symptoms in Hepatitis C Virus Infected Patients Receiving DAA-Based Therapy
por: Danilescu, Claudia Monica, et al.
Publicado: (2021)

The differential diagnosis of ulcerative colitis versus angiodysplasia of the colon with ischemic colitis
por: Popa, Denisa Elena, et al.
Publicado: (2021)

Field Cancerization in NSCLC: A New Perspective on MicroRNAs in Macrophage Polarization
por: Pirlog, Radu, et al.
Publicado: (2021)

Effectiveness and Safety of DOACs vs. Warfarin in Patients With Atrial Fibrillation and Frailty: A Systematic Review and Meta-Analysis
por: Zeng, Shan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_85hqsolqt5vb1g425cd3fajvjr